PT - JOURNAL ARTICLE AU - Anastasi, Federica AU - Fernández-Lebrero, Aida AU - Ashton, Nicholas J. AU - Ortiz-Romero, Paula AU - Torres-Torronteras, Javier AU - González-Escalante, Armand AU - Milà-Alomà, Marta AU - Contador, José AU - García-Escobar, Greta AU - Manero-Borràs, Rosa María AU - Navalpotro-Gómez, Irene AU - Sahajan, Aparna AU - Hao, Qinyu AU - Zhang, Bingqing AU - Jeromin, Andreas AU - Le Bastard, Nathalie AU - Nadal, Alicia AU - Mousavi, Tahmine AU - Kollmorgen, Gwendlyn AU - Carboni, Margherita AU - Grau-Rivera, Oriol AU - Zetterberg, Henrik AU - del Campo, Marta AU - Blennow, Kaj AU - Puig-Pijoan, Albert AU - Suárez-Calvet, Marc TI - A head-to-head comparison of plasma biomarkers to detect biologically defined Alzheimer in a memory clinic AID - 10.1101/2024.10.26.24316176 DP - 2024 Jan 01 TA - medRxiv PG - 2024.10.26.24316176 4099 - http://medrxiv.org/content/early/2024/10/27/2024.10.26.24316176.short 4100 - http://medrxiv.org/content/early/2024/10/27/2024.10.26.24316176.full AB - INTRODUCTION Blood-based biomarkers for Alzheimer’s disease (AD) have been widely studied, but direct comparisons of several biomarkers in clinical settings remain limited.METHODS In this cross-sectional study, plasma biomarkers from 197 participants in the BIODEGMAR cohort at Hospital del Mar (Barcelona) were analysed. Participants were classified based on AD cerebrospinal fluid (CSF) core biomarkers. We assessed the ability of plasma p-tau181, p-tau217, p-tau231, t-tau, and Aβ42/40 to classify Aβ status.RESULTS Plasma p-tau biomarkers had a greater diagnostic performance and larger effect sizes compared to t-tau and Aβ42/40 assays in detecting biologically defined AD. Among them, plasma p-tau217 consistently outperformed the others, demonstrating superior AUC. Furthermore, p-tau217 showed the strongest correlation between plasma and CSF levels, underscoring its potential as a reliable surrogate for CSF biomarkers.DISCUSSION Several plasma biomarkers, targeting different epitopes and using different platforms, demonstrated high performance in distinguishing biologically defined AD in a memory clinic setting.Competing Interest StatementAS, QH and BZ are employees of Alamar Biosciencies, Inc. NLB and AN are employees of Fujirebio Europe N.V. and Fujirebio Iberia, respectively. TM is an employee of Meso Scale Diagnostics, LLC. GK is a full-time employee of Roche Diagnostics GmbH. MC is a full-time employee of Roche Diagnostics International Ltd and an owner of shares in Roche. HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, LabCorp, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures sponsored by Alzecure, BioArctic, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk, Roche, and WebMD, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). AP-P has served on advisory boards for Schwabe Farma Iberica. MS-C has received in the past 36mo consultancy/speaker fees (paid to the institution) from by Almirall, Eli Lilly, Novo Nordisk, and Roche Diagnostics. He has received consultancy fees or served on advisory boards (paid to the institution) of Eli Lilly, Grifols and Roche Diagnostics. He was granted a project and is a site investigator of a clinical trial (funded to the institution) by Roche Diagnostics. In-kind support for research (to the institution) was received from ADx Neurosciences, Alamar Biosciences, ALZPath, Avid Radiopharmaceuticals, Eli Lilly, Fujirebio, Janssen Research & Development, Meso Scale Discovery, and Roche Diagnostics; MS-C did not receive any personal compensation from these organizations or any other for-profit organization.Funding StatementFA receives funding from the JDC2022-049347-I grant, funded by the MCIU/AEI/10.13039/501100011033 and the European Union NextGenerationEU/PRTR. HZ is a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (#2023-00356; #2022-01018 and #2019-02397), the European Union s Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer s Association (#ADSF-21-831376-C, #ADSF-21-831381-C, #ADSF-21-831377-C, and #ADSF-24-1284328-C), the European Partnership on Metrology, co-financed from the European Union s Horizon Europe Research and Innovation Programme and by the Participating States (NEuroBioStand, #22HLT07), the Bluefield Project, Cure Alzheimer s Fund, the Olav Thon Foundation, the Erling-Persson Family Foundation, Familjen Ronstroms Stiftelse, Stiftelsen for Gamla Tjanarinnor, Hjarnfonden, Sweden (#FO2022-0270), the European Union s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme - Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003). MS-C receives funding from the European Research Council (ERC) under the European Union s Horizon 2020 research and innovation programme (Grant agreement No. 948677); ERA PerMed (ERAPERMED2021-184); Project PI19/00155 and PI22/00456, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union; and from a fellowship from la Caixa Foundation (ID 100010434) and from the European Union s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 847648 (LCF/BQ/PR21/11840004). Alamar, ALZpath, Fujirebio, MSD and Roche Diagnostics provided reagents and/or biomarker measurements in-kind. A few employees of these companies, listed as co-authors, made direct contributions to this research (see the Contributors section). The companies were not involved in the study design, or the analysis and interpretation of the data. The corresponding authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The BIODEGMAR study was approved by the Independent Ethics Committee Parc de Salut Mar, Barcelona (CEIC PSMAR, project code 2018/7805I). All participants from BIODEGMAR provided informed consent.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll requests for raw and analysed data and materials will be promptly reviewed by the senior authors to verify whether the request is subject to any intellectual property or confidentiality obligations. Bulk Anonymized data can be shared by request from any qualified investigator for the sole purpose of replicating procedures and results presented in the article, providing data transfer agrees with EU legislation and decisions by the IRB of each participating center.